Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy

1 Oct 2019

Abstract excerpt

Monoclonal antibodies (mAbs) targeting the oncogenic receptor tyrosine kinase ERBB2/HER2, such as Trastuzumab, are the standard of care therapy for breast cancers driven by ERBB2 overexpression and activation. However, a substantial proportion of patients exhibit de novo resistance. Here, by comparing matched Trastuzumab-naive and post-treatment patient samples from a neoadjuvant trial, we link resistance with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31597089
DOI: 10.1016/j.celrep.2019.08.105

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted TherapyPMID 31597089Read ↗

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesSemantic proximity Read ↗

H3K27me3 is a determinant of chemotolerance in triple-negative breast cancerSemantic proximity Read ↗

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.Semantic proximity Read ↗

Chromatin Modifications Sequentially Enhance ErbB2 Expression in ErbB2-Positive Breast CancersSemantic proximity Read ↗

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor ImmunotherapySemantic proximity Read ↗

Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatmentsSemantic proximity Read ↗

EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.Semantic proximity Read ↗

Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistanceSemantic proximity Read ↗

EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomasSemantic proximity Read ↗

H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasisSemantic proximity Read ↗

CBX2 suppresses interferon signaling to diminish tumor immunogenicity via a noncanonical corepressor complexSemantic proximity Read ↗

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.